WallStSmart

Gilead Sciences Inc (GILD)vsQMMM Holdings Limited Ordinary Shares (QMMM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Gilead Sciences Inc generates 1569105% more annual revenue ($29.44B vs $1.88M). GILD leads profitability with a 28.9% profit margin vs -1.5%. GILD earns a higher WallStSmart Score of 72/100 (B).

GILD

Strong Buy

72

out of 100

Grade: B

Growth: 5.3Profit: 9.5Value: 10.0Quality: 5.5
Piotroski: 6/9

QMMM

Avoid

14

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 4.39
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GILDUndervalued (+53.9%)

Margin of Safety

+53.9%

Fair Value

$299.95

Current Price

$138.26

$161.69 discount

UndervaluedFair: $299.95Overvalued

Intrinsic value data unavailable for QMMM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GILD6 strengths · Avg: 9.3/10
PEG RatioValuation
0.3810/10

Growing faster than its price suggests

Return on EquityProfitability
40.7%10/10

Every $100 of equity generates 41 in profit

Operating MarginProfitability
37.4%10/10

Strong operational efficiency at 37.4%

Market CapQuality
$171.45B9/10

Large-cap with strong market position

Profit MarginProfitability
28.9%9/10

Keeps 29 of every $100 in revenue as profit

EPS GrowthGrowth
23.4%8/10

Earnings expanding 23.4% YoY

QMMM2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.3910/10

Safe zone — low bankruptcy risk

Areas to Watch

GILD1 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

QMMM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
519.1x2/10

Trading at 519.1x book value

Return on EquityProfitability
-2.0%2/10

ROE of -2.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : GILD

The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.

Bull Case : QMMM

The strongest argument for QMMM centers on Debt/Equity, Altman Z-Score.

Bear Case : GILD

The primary concerns for GILD are Revenue Growth.

Bear Case : QMMM

The primary concerns for QMMM are EPS Growth, Piotroski F-Score, Price/Book.

Key Dynamics to Monitor

GILD profiles as a value stock while QMMM is a turnaround play — different risk/reward profiles.

GILD is growing revenue faster at 4.7% — sustainability is the question.

GILD generates stronger free cash flow (3.1B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GILD scores higher overall (72/100 vs 14/100), backed by strong 28.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Gilead Sciences Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

QMMM Holdings Limited Ordinary Shares

COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA

QMMM Holdings Limited, provides digital media advertising and marketing production services primarily in Hong Kong.

Visit Website →

Want to dig deeper into these stocks?